Scarica l'app Stockscreener
11.43
0.18%
0.02
Dopo l'orario di chiusura:
11.43
Precedente Chiudi:
$11.41
Aprire:
$11.5782
Volume 24 ore:
31,384
Relative Volume:
0.23
Capitalizzazione di mercato:
$219.58M
Reddito:
$54,000
Utile/perdita netta:
$-210.26M
Rapporto P/E:
-14.47
EPS:
-0.79
Flusso di cassa netto:
$-159.01M
1 W Prestazione:
+1.33%
1M Prestazione:
+3.72%
6M Prestazione:
-13.59%
1 anno Prestazione:
-59.18%
Intervallo 1D:
$11.18
$11.58
Intervallo di 1 settimana:
$10.76
$11.67
Portata 52W:
$7.65
$32.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Nome
Lyell Immunopharma Inc
Settore
Industria
Telefono
650 695-0677
Indirizzo
201 HASKINS WAY, SOUTH SAN FRANCISCO
Confronta LYEL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
11.43 | 212.86M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.62 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.80 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.23 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
722.01 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
336.26 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-30 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-06-27 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-11-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2021-07-12 | Iniziato | BofA Securities | Buy |
| 2021-07-12 | Iniziato | Goldman | Buy |
| 2021-07-12 | Iniziato | JP Morgan | Overweight |
| 2021-07-12 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Lyell Immunopharma Inc Borsa (LYEL) Ultime notizie
Using Bollinger Bands to evaluate Lyell Immunopharma Inc.Entry Point & Short-Term Trading Opportunity Alerts - Newser
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-To-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma - MarketScreener
Lyell Immunopharma Announces the Initiation of a Phase 3 - GlobeNewswire
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee - Stock Titan
Price action breakdown for Lyell Immunopharma Inc.Bond Market & Real-Time Stock Price Movement Reports - Newser
Using RSI to spot recovery in Lyell Immunopharma Inc.July 2025 EndofMonth & Real-Time Sentiment Analysis - Newser
What the charts say about Lyell Immunopharma Inc. today2025 Short Interest & Consistent Profit Alerts - Newser
Order flow analysis tools used on Lyell Immunopharma Inc.Market Risk Analysis & Consistent Return Strategy Ideas - Newser
Using data models to predict Lyell Immunopharma Inc. stock movementWatch List & Technical Buy Zone Confirmation - Newser
Sector ETF performance correlation with Lyell Immunopharma Inc.Forecast Cut & Precise Buy Zone Identification - Newser
Will Lyell Immunopharma Inc. stock go up soon2025 Earnings Impact & Weekly High Momentum Picks - Newser
Lyell Immunopharma’s Strategic Momentum in CAR T-Cell Innovation and Commercial Readiness - AInvest
Can Traders Expect Breakout From Lyell Immunopharma Inc. This Week getLinesFromResByArray error: size == 0 - kangso.co.kr
Is Lyell Immunopharma Inc. in a bullish channelJuly 2025 Breakouts & High Accuracy Investment Signals - khodrobank.com
Lyell Immunopharma to Present at Investor Conferences - AInvest
Lyell Immunopharma Announces Participation in September Investor Conferences - GlobeNewswire
Clinical-Stage CAR T-Cell Therapy Developer Lyell Immunopharma Announces Key September Investor Presentations - Stock Titan
Is Lyell Immunopharma Inc. a good stock for dollar cost averagingJuly 2025 Opening Moves & Target Return Focused Stock Picks - khodrobank.com
What candlestick patterns are forming on Lyell Immunopharma Inc.Weekly Trade Analysis & Free Expert Approved Momentum Trade Ideas - Newser
Can Lyell Immunopharma Inc. reach all time highs this yearTrend Reversal & Smart Allocation Stock Reports - khodrobank.com
Multi factor analysis applied to Lyell Immunopharma Inc.2025 Trade Ideas & Scalable Portfolio Growth Ideas - Newser
Detecting price anomalies in Lyell Immunopharma Inc. with AIEarnings Overview Summary & AI Powered Market Entry Ideas - Newser
What technical models suggest about Lyell Immunopharma Inc.’s comebackCEO Change & Short-Term High Return Ideas - Newser
Detecting support and resistance levels for Lyell Immunopharma Inc.Entry Point & Safe Entry Momentum Stock Tips - Newser
Identifying reversal signals in Lyell Immunopharma Inc.July 2025 Analyst Calls & Daily Oversold Stock Bounce Ideas - Newser
Applying big data sentiment scoring on Lyell Immunopharma Inc.Market Activity Summary & Accurate Entry/Exit Alerts - Newser
Visual trend scoring systems applied to Lyell Immunopharma Inc.Stock Surge & Free Safe Entry Trade Signal Reports - Newser
What momentum shifts mean for Lyell Immunopharma Inc.Market Risk Summary & Entry Point Confirmation Alerts - Newser
Custom strategy builders for tracking Lyell Immunopharma Inc.Quarterly Portfolio Report & Smart Swing Trading Techniques - Newser
Real time scanner hits for Lyell Immunopharma Inc. explained2025 Pullback Review & Verified Momentum Watchlists - Newser
Regression analysis insights on Lyell Immunopharma Inc. performanceMarket Sentiment Report & Daily Momentum Trading Reports - Newser
How to escape a deep drawdown in Lyell Immunopharma Inc.July 2025 Highlights & AI Driven Price Predictions - Newser
Is Lyell Immunopharma Inc. a candidate for recovery playNew Guidance & Free Accurate Trade Setup Notifications - Newser
Lyell Immunopharma Inc Azioni (LYEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.14%
1.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):